SMMT Clinical trials

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Published August 14, 2025 at 11:00 AM

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona on Sunday, September 7, 2025, at 8:15am CET (2:15am ET)

Related Questions

How will the presentation of HARMONi trial data at WCLC 2025 affect Summit Therapeutics' stock price? What are the key efficacy and safety endpoints expected to be highlighted from the ivonescimab Phase III data? How does ivonescimab’s mechanism of action compare to existing lung‑cancer therapies and other bispecific antibodies in development? What is the anticipated timeline for regulatory filing and potential FDA approval following the data release? How might the Phase III data influence market expectations for Summit’s future revenue and cash‑flow forecasts? What are the potential risks or uncertainties surrounding the data presentation that could impact investor sentiment? How does the anticipated market size for ivonescimab’s target indication compare to competitors’ pipelines? What is the expected impact of the HARMONi trial results on Summit’s valuation multiples relative to peers? Will the data release affect the company’s upcoming earnings guidance or financial outlook? Will the HARMONi trial results trigger any new partnership or licensing opportunities for Summit Therapeutics?